Home/Filings/4/0001181431-13-006146

4//SEC Filing

NEWCOGEN EQUITY INVESTORS LLC 4

Accession 0001181431-13-006146

CIK 0001407038other

View on SEC.gov Company Profile

Filed

Jan 31, 7:00 PM ET

Accepted

Feb 1, 4:53 PM ET

Size

27.7 KB

Accession

0001181431-13-006146

Insider Transaction Report

Form 4

Period: 2013-01-30

BG Medicine, Inc.BGMD

AFEYAN NOUBAR

Director10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)

Holdings

Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232

KANIA EDWIN M JR

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)

Holdings

Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424

Applied Genomic Technology Capital Fund LP

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)

Holdings

Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232

NEWCOGEN GROUP LLC

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)

Holdings

Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424

AGTC Partners, L.P.

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)

Holdings

Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232

AGTC ADVISORS FUND LP

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)

Holdings

Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By LLC)
92,126

Flagship Pioneering, LLC

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)

Holdings

Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232
Common Stock
(indirect: By LLC)
92,294
Common Stock
(indirect: By LLC)
92,126

NewcoGen Group, Inc.

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)

Holdings

Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By LLC)
92,294

NEWCOGEN EQUITY INVESTORS LLC

10% Owner

Transactions

Purchase
Common Stock
2013-01-30$2.00/sh+250,000$500,000→ 2,434,800 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+125,000$250,000→ 651,560 total(indirect: By LLC)
Purchase
Common Stock
2013-01-30$2.00/sh+1,050,000$2,100,000→ 1,764,286 total(indirect: By Flagship Ventures Fund 2007, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+75,000$150,000→ 215,013 total(indirect: By AGTC Advisors Fund, L.P.)
Purchase
Common Stock
2013-01-30$2.00/sh+500,000$1,000,000→ 2,851,447 total(indirect: By Applied Genomic Technology Capital Fund, L.P.)

Holdings

Common Stock
(indirect: By LLC)
92,126
Common Stock
(indirect: By OneLiberty Ventures 2000 L.P.)
80,424
Common Stock
(indirect: By OneLiberty Advisors Fund 2000 L.P.)
4,232
Common Stock
(indirect: By LLC)
92,294

Footnotes (3)

[F1]NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG"), NewcoGen Equity Investors LLC ("NEI"), NewcoGen-Long Reign Holding LLC ("NGLRH") and ST NewcoGen LLC ("STN", and together with NGG, NEI and NGLRH, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund, L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
[F2]Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
[F3]Noubar Afeyan and Edwin M. Kania, Jr. are managing members of OneLiberty Partners 2000, LLC, which is the general partner of OneLiberty Advisors Fund 2000 L.P. ("OLA") and OneLiberty Ventures 2000 L.P. ("OLV"), and may be deemed to beneficially own the securities held by OLA and OLV. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Documents

1 file

4
rrd368067.xmlPrimary
FORM 4 - FLAGSHIP

Issuer

BG Medicine, Inc.

CIK 0001407038

→

Entity typeother

Related Parties

filerCIK 0001097546

Filing Metadata

Form type: 4
Filed: Jan 31, 7:00 PM ET
Accepted: Feb 1, 4:53 PM ET
Size: 27.7 KB

View on SEC.gov